Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Bank of America Upgrades T-Mobile to Buy, Says LEO Satellite Fears Are Overdone 
Citi Raises TSMC Price Target as AI Chip Demand Strengthens Growth Outlook 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Gold Surges Past $4150 on Dovish Fed Signals and Weak Jobs Data; Bullish Outlook Prevails 
Trump has made more than $1 billion from crypto in a year. How? 
Goldman Sachs Says China Competition Weighs More on EU Growth Than Trade Deficit 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
In a rebuke to Trump, the Supreme Court rules that birthright citizenship is the law of the land 
For the past six months US small caps are performing better than large counterparts as measured by Russell 2000 and S&P 500 indices. Since late october 2014, Russell 2000 rose 13.7% compared to 4.4% rise in S&P 500. Chart courtesy Sober look
- Investors remain bullish on US stocks, however exercising cautions over stronger US dollar.
- Large corporate houses that have presence across globe are expected to suffer from stronger US dollar as export revenues and royalty payments will get affected.
- According to EPFR, intelligence provider on Global fund statistics after nearly $31.5 billion withdrawal for the sector in 2014, this year they have started attracting flows. Investors expect small companies to benefit most out of US recovery amid stronger dollar.
- Average sales per share is up 6.6% this year for S&P600 companies so far this year, compared to 0.1% for large caps.
- UBS expects earnings for small companies would be in double digit this year whereas average for large caps would remain in single.
- Investors remain most bullish healthcare and pharmaceuticals whereas energy sector is expected to do worst.
- Bluebird bio returned more than 300% since February 2014, followed by Agios Pharma and Achillion Pharma both of which have returned more than 200%.
